Annexon lands up to $200M debt facility from Oxford Finance
What's the deal? Annexon Biosciences (Nasdaq: ANNX) has secured a strategic credit facility of up to $200 million from Oxford FinanceDealroom has a profile for this one. Try Dealroom →. The Brisbane, California biopharmaceutical company drew an initial $50 million at closing.
How it's structured: An additional $100 million becomes available once Annexon hits certain milestones tied to its vonaprument and tanruprubart programs. The final $50 million is subject to lender approval.
What Annexon does: It develops targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million people worldwide. Its approach targets C1q, the initiating molecule of an inflammatory pathway that, when misdirected, can cause tissue damage and loss of function.
What's the endgame? The company is preparing for potential global commercialisation of vonaprument and tanruprubart, its two lead programs approaching registration. The debt is non-dilutive, meaning it does not require issuing new equity.
Why now? The financing arrives as both programs move toward registration, a capital-intensive stage before commercial launch. "Access to this non-dilutive capital further diversifies our capital structure, strengthens our balance sheet, and accelerates our near and long-term growth strategy," said Douglas Love, president and chief executive officer of Annexon.
The signal: Milestone-based, non-dilutive debt is an increasingly common way for late-stage biotechs to fund the run-up to commercialisation without diluting shareholders. Oxford Finance framed the structure as a vote of confidence — a "milestone-based financing facility that reflects our confidence in Annexon's strategy, execution," said managing director Kirk Andrews.
Read more: wallstreet-online.de
Image credit: Generated with Gemini
